Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
- 1 January 1997
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (1) , 204-211
- https://doi.org/10.1128/aac.41.1.204
Abstract
Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods. LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC50, 0.03 micrograms/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 micrograms/ml). It has limited activity against gram-negative anaerobes.Keywords
This publication has 5 references indexed in Scilit:
- In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobialDiagnostic Microbiology and Infectious Disease, 1994
- Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States I. Study on the threat of emerging resistances: Real or perceived?Diagnostic Microbiology and Infectious Disease, 1994
- Hospital-acquired infections: diseases with increasingly limited therapies.Proceedings of the National Academy of Sciences, 1994
- The in-vitro activity of a new highly active quinolone, DU-6859aJournal of Antimicrobial Chemotherapy, 1993
- Pneumococcal resistance to antibioticsClinical Microbiology Reviews, 1990